TERT-CLPTM1 locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma

Figures & data

Figure 1 Telomere length difference according to rs401681 polymorphisms. Telomere length was not different according to rs401681 polymorphisms (p=0.802).

Table 1 Clinicopathologic characteristics of rs401681 polymorphism in hepatocellular carcinoma

	rs401681 (TERT-CLPTM1L locus)			p-value
	CC	CT	TT
Total	80 (51.3)	62 (39.7)	14 (9.0)
Age	57.6±11.9	56.8±10.0	56.0±10.5	0.626
Sex				0.564
Male	58 (49.6)	47 (40.2)	12 (10.3)
Female	22 (56.4)	15 (38.5)	2 (5.1)
Infection				0.165
Alcohol	8 (38.1)	12 (57.1)	1 (4.8)
HBV	31 (56.4)	16 (29.1)	8 (14.5)
HCV	1 (25.0)	3 (75.0)	0 (0)
Others	40 (52.6)	31 (40.8)	5 (6.6)
AST				0.655
<40 U/L	51 (52.6)	36 (37.1)	10 (10.3)
≥40 U/L	29 (50.0)	25 (43.1)	4 (6.9)
ALT				0.637
<40 U/L	58 (52.7)	41 (37.3)	11 (10.0)
≥40 U/L	22 (48.9)	20 (44.4)	3 (6.7)
Tumor size				0.927
<5 cm	47 (50.5)	37 (39.8)	9 (9.7)
≥5 cm	33 (52.4)	25 (39.7)	5 (7.9)
AJCC T stage				0.003
T1	4 (30.8)	4 (30.8)	5 (38.5)
T2	55 (49.5)	50 (45.0)	6 (5.4)
T3	20 (66.7)	7 (23.3)	3 (10.0)
T4	1 (50.0)	1 (50.0)	0 (0)
UICC				0.008
I	5 (35.7)	4 (28.6)	5 (35.7)
II	54 (49.5)	49 (45.0)	6 (5.5)
III	20 (62.5)	9 (28.1)	3 (9.4)
IV	1 (100)	0 (0)	0 (0)
TERT mutation				0.486
(+)	23 (54.8)	14 (40.5)	5 (11.9)
(−)	54 (48.6)	48 (43.2)	9 (8.1)

Notes: Values are presented as number (%) unless otherwise indicated. p-values of χ² tests are indicated.

Abbreviations: AJCC, American Joint Committee on Cancer; ALT, alanine transaminase; AST, aspartate transaminase; HBV, hepatitis B virus; HCV, hepatitis C virus; TERT, telomerase reverse transcriptase; UICC, Union for International Cancer Control.

Figure 2 Kaplan–Meier cures for disease-free survival (A, B) and overall survival (C, D) of HCC patients according to rs401681 polymorphisms.

Abbreviation: HCC, hepatocellular carcinoma.

Table 2 Multivariate analysis of the prognostic values of various factors in HCC

Variable	DFS			OS
	p-value	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI
rs401681	0.040	1.88	1.03–3.44	0.80	1.07	0.63–1.83
Age	0.824	1.00	0.98–1.03	0.570	1.01	0.98–1.04
Sex	0.032	1.93	1.06–3.53	0.007	3.02	1.36–6.68
Tumor size	0.036	1.09	1.00–1.19	0.001	1.18	1.08–1.29
AST	0.699	1.00	0.99–1.02	0.602	1.00	0.99–1.02
ALT	0.812	1.00	0.68–1.08	0.563	1.01	0.99–1.02

Notes: Hazard ratio (95% CI) of multivariate analysis. p-values of χ² tests are indicated; p<0.05, statistically significant.

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; DFS, disease-free survival; HCC, hepatocellular carcinoma; OS, overall survival.